Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.
Addiction, November 2009
—
BACKGROUND: We consider how many cannabis users may need to be prevented in order to prevent one case of schizophrenia or psychosis [defined as number needed to prevent (NNP)]. METHOD: Calculation for England and Wales using best available estimates of: incidence of schizophre…
Molecular Cancer Therapeutics, November 2009
—
Cannabinoids have been reported to possess antitumorogenic activity. Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis. We have shown that the cannabinoid receptors CB1 and CB2 ar…
Cochrane Database of Systematic Reviews, 7 October 2009
—
BACKGROUND: Gilles de la Tourette Syndrome (GTS) is a developmental neuropsychiatric disorder characterised by the presence of chronic motor and phonic tics. Drugs currently used in the treatment of GTS either lack efficacy or are associated with intolerable side effects. Ther…
British Journal of Cancer, 15 September 2009
—
BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…
Schizophrenia Research, September 2009
—
A recent systematic review concluded that cannabis use increases risk of psychotic outcomes independently of confounding and transient intoxication effects. Furthermore, a model of the association between cannabis use and schizophrenia indicated that the incidence and prevalen…
Journal of Clinical Psychopharmacology, June 2009
—
We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. I…
Seminars in Immunopathology, June 2009
—
Endocannabinoids are endogenous bioactive lipid mediators present both in the brain and various peripheral tissues, which exert their biological effects via interaction with specific G-protein-coupled cannabinoid receptors, the CB(1) and CB(2). Pathological overactivation of t…
World Journal of Gastroenterology, 14 March 2009
—
Cannabis is a common drug of abuse that is associated with various long-term and short-term adverse effects. The nature of its association with vomiting after chronic abuse is obscure and is underrecognised by clinicians. In some patients this vomiting can take on a pattern si…
CNS Neuroscience & Therapeutics, Winter 2009
—
This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment-resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD). METHODS: Charts of 47 patients diagnosed with PTSD an…
Journal of Child and Adolescent Psychopharmacology, December 2008
—
OBJECTIVE: Co-occurrence of substance use and bipolar disorders is both common and associated with poor treatment response and greater functional impairment than either disorder alone. The neurophysiological correlates of this co-morbidity however, remain unclear. In this pilo…
Journal of Cannabis Therapeutics, October 2008
—
Cannabis has an ancient tradition of usage as a medicine in obstetrics and gynecology. This study presents that history in the literature to the present era, compares it to current ethnobotanical, clinical and epidemiological reports, and examines it in light of modern develop…
Cancer Epidemiology Biomarkers & Prevention, October 2008
—
BACKGROUND: Despite several lines of evidence suggesting the biological plausibility of marijuana being carcinogenic, epidemiologic findings are inconsistent. We conducted a population-based case-control study of the association between marijuana use and the risk of lung and u…